MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. - Chien AJ; Tripathy D; Albain KS; Symmans WF; Rugo HS; Melisko ME; Wallace AM; Schwab R; Helsten T; Forero-Torres A; Stringer-Reasor E; Ellis ED; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020)